Modeling of commercial autologous cell therapy manufacturing using simulation and optimization
January 27-31, 2019
Autologous cell therapy is a groundbreaking treatment for patients that also has distinct scale-up and commercialization challenges. In this presentation, we discuss the differences between traditional life science versus autologous manufacturing, the underlying mathematical theory, and the use of optimization and simulation to accurately identify and resolve the capacity issues unique to this market. We also look ahead to the future of autologous manufacturing and the issues that must be addressed as more drugs become available commercially worldwide.
David Zhang, "Modeling of commercial autologous cell therapy manufacturing using simulation and optimization" in "Advancing Manufacture of Cell and Gene Therapies VI", Dolores Baksh, GE Healthcare, USA Rod Rietze, Novartis, USA Ivan Wall, Aston University, United Kingdom Eds, ECI Symposium Series, (2019). http://dc.engconfintl.org/cell_gene_therapies_vi/72